IN3BIO is a UK-based biotechnology company dedicated to developing new therapeutics that can provide cancer patients with new and effective treatments
MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients
09. März 2022 10:08 ET | IN3BIO
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable...